Zevra Therapeutics Inc (FRA:1GDA)
€ 4.14 -0.08 (-1.9%) Market Cap: 173.41 Mil Enterprise Value: 165.56 Mil PE Ratio: 0 PB Ratio: 3.90 GF Score: 50/100

Q2 2023 Zevra Therapeutics Inc Earnings Call Transcript

Aug 14, 2023 / 12:30PM GMT
Release Date Price: €4.68 (+4.46%)
Operator

Good morning, and welcome to the Zevra Therapeutics Second Quarter 2023 Corporate and Financial Results Conference Call. (Operator Instructions) Please be advised that today's call is being recorded.

I will now turn the call over to Nichol Ochsner, Zevra Therapeutics Vice President, Investor Relations and Corporate Communications. Thank you. You may begin.

Nichol L. Ochsner
Zevra Therapeutics, Inc. - VP of IR & Corporate Communications

Good morning, and thank you for joining us today to review Zevra Therapeutics progress in the second quarter of 2023, outlining our clinical progress, operational achievements, and financial results.

Before we get started, let me take a moment to provide some important information. First, I encourage you to access the webcast slides and the press release both of which were released this morning and are available in the Investors Section of Zevra's website. These documents provide comprehensive insights into our results for this quarter.

As we move forward with the presentation, it is important to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot